BioStock: Cyxone reports Q3 and presents T20K

Malmö-based Cyxone recently published its report for the third quarter, which testifies that the company is focusing on the phase IIb study with Rabeximod in rheumatoid arthritis. At the same time as the release of the report, the latest advances in the T20K program were presented at a scientific conference in the Netherlands. BioStock contacted acting CEO Carl-Magnus Högerkorp for an update.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/cyxone-reports-q3-and-presents-t20k/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se